A | B | C | D | E | F | G | H | |
---|---|---|---|---|---|---|---|---|
1 | Evidence | Therapeutic Class | Drug Name | Brand Name | Target | Patients | Results | Reference |
2 | Phase 2 Trial | Immune Checkpoint Inhibitor | Durvalumab + tremelimumab | Imfinzi + (no brand name) | PD-L1 + CTLA4 | 5 | 1 PR | Somaiah et al. Lancet Oncol 2022 |
3 | Phase 2 Trial | Immune Checkpoint Inhibitor | Pembrolizumab | Keytruda | PD-1 | 34 | 3 PR, median PFS 6.6 months | Blay et al. J Clin Oncol 2021 |
4 | Phase 2 Trial | Targeted Therapy | Apatinib | Aitan | VEGF | 27 | 8 PR, median PFS 18 months | Liu et al. Lancet Oncol 2020 |
5 | Phase 2 Trial | Therapeutic Vaccine | GI-6301 | Tarmogen | Brachyury | 24 | No difference in ORR for vaccine vs. placebo | DeMaria et al. J Clin Oncol 2020 |
6 | Phase 2 Trial | Immune Checkpoint Inhibitor | Pembrolizumab | Keytruda | PD-1 | 12 | 1 PR, median PFS 5.7 months | Blay et al. Ann Oncol. 2019 |
7 | Phase 2 Trial | Targeted Therapy | Dasatinib | Sprycel | PDGRF, c-KIT | 32 | median PFS 6.3 months | Schuetze et al. Cancer 2016 |
8 | Phase 2 Trial | Targeted Therapy | Sorafenib | Nexavar | multiple RTK | 27 | 1 PR, 73% SD (at 9 months) | Bompas et al. Ann Oncol. 2015 |
9 | Phase 2 Trial | Targeted Therapy | Lapatinib | Tykerb | EGFR | 18 | 13 SD | Stacchiotti et al. Ann Oncol. 2013 |
10 | Phase 2 Trial | Targeted Therapy | Imatinib | Gleevec | PDGFR | 50 | 1 PR, 70% SD, median PFS 9.2 months | Stacchiotti et al. Journal of Clinical Oncology, 2012 |
11 | Phase 2 Trial | Targeted Therapy | Imatinib + everolimus | Gleevec + Afinitor | PDGFR + mTOR | 43 | 1 PR, 86% SD | Stacchiotti et al. Cancer, 2018 |
12 | Phase 2 Trial | Targeted Therapy | Sunitinib | Sutent | multiple RTK | 9 | 4 SD | George et al. J Clin Oncol. 2009 |
13 | Phase 2 Trial | Cytotoxic Therapy | Rubitecan | Orathecin | N/A | 15 | 1 PR | Chugh et al. J Clin Oncol. 2005 |
14 | ||||||||
15 | Phase 1 Trial | Therapeutic Vaccine | MVA-BN-Brachyury | Brachyury | 10 | 1 PR, 2 SD | DeMaria et al. J Clin Oncol 2021 | |
16 | Phase 1 Trial | Targeted Therapy + Radiation | Nilotinib | Tasigna | PDGFR | 23 | median PFS 58.15 months | Cote et al. Int J Radiat Oncol Biol Phys 2018 |
17 | Phase 1 Trial | Targeted Therapy | Tazemetostat | Tazverik | EZH2 | 2 | 1 CR, 1 PR | Chi et al. 2017 (Abstract) |
18 | Phase 1 Trial | Therapeutic Vaccine | GI-6301 | Tarmogen | Brachyury | 10 | median PFS 8.3 months | Heery et al. Cancer Immunol Res. 2015 |
19 | Phase 1 Trial | Targeted Therapy + Cytotoxic Therapy | Imatinib mesyate + metronomic cyclophosphamide | Gleevec + Cytoxan | PDGFR | 7 | median PFS 10.2 months | Adenis et al. British Journal of Cancer, 2013 |
20 | ||||||||
21 | Case Series | Cytotoxic Therapy +/- Targeted Therapy | Cisplatin +/- imatinib | Platinol +/- Gleevec | PDGFR (imatinib) | 32 | 27 SD, median PFS 8 months | Baldi et al. Cancer 2022 |
22 | Case Series | Immune Checkpoint Inhibitor | Nivolumab | Opdivo | PD-1 | 2 | 1 PR | Williamson et al. NPJ Precis Oncol 2021 |
23 | Case Series | Targeted Therapy | Erlotinib | Tarceva | EGFR | 31 | 4 PR, 14 SD, median PFS 6.2 months | Mir et al. J Clin Oncol 2021 |
24 | Case Series | Targeted Therapy | Imatinib | Gleevec | PDGFR | 62 | 3 PR, 43 SD | Lebellec et al. Eur J Cancer 2017 |
25 | Case Series | Targeted Therapy | Erlotinib | Tarceva | EGFR | 5 | 1 PR, 4 SD | Lebellec et al. Eur J Cancer 2017 |
26 | Case Series | Targeted Therapy | Sorafenib | Nexavar | multiple RTK | 11 | 1PR, 9 SD | Lebellec et al. Eur J Cancer 2017 |
27 | Case Series | Targeted Therapy | Pazopanib + Sunitinib | Votrient + Sutent | multiple RTK | 5 | median PFS 8.5 months | Lipplaa et al. Clin Sarcoma Res 2016 |
28 | Case Series | Targeted Therapy | Imatinib | Gleevec | PDGFR | 46 | 34 SD | Hindi et al. Euro J Cancer 2015 |
29 | Case Series | Targeted Therapy | Imatinib | Gleevec | PDGFR | 2 | 2 SD | Rohatgi et al. Eurasian J Med 2015 |
30 | Case Series | Targeted Therapy | Erlotinib + Bevacizumab | Tarceva + Avastin | EGFR, VEGF | 3 | 3 SD | Asklund et. al. Acta Oncol. 2014 Jan |
31 | Case Series | Targeted Therapy | Imatinib | Gleevec | PDGFR | 17 | 1 SD | Ferraresi et al. BMC Cancer. 2010 |
32 | Case Series | Targeted Therapy | Imatinib + Sirolimus | Gleevec + Rapamune | PDGFR + mTOR | 9 | 8 SD | Stacchiotti et al. Ann Oncol. 2009 |
33 | Case Series | Targeted Therapy | Imatinib | Gleevec | PDGFR | 3 | 1 PR, 2 SD | Geoerger et al. Eur J Cancer 2009 |
34 | Case Series | Targeted Therapy | Imatinib | Gleevec | PDGFR | 6 | 4 symptomatic improvement | Casali et al. Cancer 2004 |
35 | ||||||||
36 | Case Report | Cytotoxic Therapy | Ifosfomide + etoposide; vincristine + doxorubicin + cyclophosphamide; ifosfamide + carboplatin + etoposide; pazopanib | 1 (pediatric) | 1 PR (>90%, for 5 years) | Miyahara et al. J Pediatr Hematol Oncol 2020 | ||
37 | Case Report | Targeted Therapy | Pazopanib | Votrient | VEGFR/PDGFR | 1 | 1 SD | Ribeiro et al. Case Rep Oncol Med. 2018 |
38 | Case Report | Targeted Therapy | Temsirolimus | Torisel | mTOR | 1 | 1 SD | Lebellec et al. Eur J Cancer 2017 |
39 | Case Report | Immune Checkpoint Inhibitor | Nivolumab | Opdivo | PD-1 | 1 | 1 PR | Migliorini et al. OncoImmunology 2017 |
40 | Case Report | Immune Checkpoint Inhibitor | Pembrolizumab | Keytruda | PD-1 | 1 | 1 PR | Migliorini et al. OncoImmunology 2017 |
41 | Case Report | Targeted Therapy | Pazopanib | Votrient | VEGFR/PDGFR | 1 | 1PR | Jagersberg et al. Acta Neurochir. 2017 |
42 | Case Report | Therapeutic Vaccine | MVX-ONCO-1 | N/A | 1 | 1 PR | Migliorini et al. OncoImmunology 2017 | |
43 | Case Report | Targeted Therapy | Erlotinib + Linsitinib | Tarceva + Linsitinib | EGFR + IGF1R | 1 | 1 PR | Aleksic et al. Frontiers in Oncology 2017 |
44 | Case Report | Targeted Therapy | Erlotinib | Tarceva | EGFR | 1 | 1 PR | Houessinon et al. Case Reports Oncol. 2015 |
45 | Case Report | Targeted Therapy | Sorafenib | Nexavar | multiple RTK | 1 | 1 SD | Svoboda et al. J Am Acad Dermatol. 2012 |
46 | Case Report | Cytoxoic Therapy | Vincristine + cyclophosphamide +doxorubicin + etoposide + ifosfamide | 1 (pediatric) | 1 CR (durable for 3+ years) | Al-Rahawan MM et al. Pediatr Blood Cancer 2012 | ||
47 | Case Report | Targeted Therapy | Thalidomide | Thalomide | 1 | 1 PR | Chay et al. J Clin Oncol. 2011 | |
48 | Case Report | Targeted Therapy | Cetuximab + Gefitinib | Erbitux + Iressa | EGFR | 1 | 1 PR | Linden et al. Acta Oncol. 2009 |
49 | Case Report | Targeted Therapy | Erlotinib | Tarceva | EGFR | 1 | 1 PR | Singhal et al. Anticancer Drugs. 2009 |
50 | Case Report | Targeted Therapy | Cetuximab + Gefitinib | Erbitux + Iressa | EGFR | 1 | 1 PR | Hof et al. Onkologie. 2006 |
51 | Case Report | Targeted Therapy + Cytotoxic Therapy | Thalidomide + liposomal doxorubicin | Thalomid + Doxil | 1 | 1 SD | Schönegger et al. Anticancer Drugs. 2005 | |
52 | Case Report | Cytotoxic Therapy | Ifosfamide + doxorubicin | 1 (pediatric) | 1 PR | Scimeca eta al. J Pediatr Hematol Oncol. 1996 | ||
53 | ||||||||
54 | ||||||||
55 | ||||||||
56 | ||||||||
57 | ||||||||
58 | ||||||||
59 | ||||||||
60 | ||||||||
61 | ||||||||
62 | ||||||||
63 | ||||||||
64 | ||||||||
65 | ||||||||
66 | ||||||||
67 | ||||||||
68 | ||||||||
69 | ||||||||
70 | ||||||||
71 | ||||||||
72 | ||||||||
73 | ||||||||
74 | ||||||||
75 | ||||||||
76 | ||||||||
77 | ||||||||
78 | ||||||||
79 | ||||||||
80 | ||||||||
81 | ||||||||
82 | ||||||||
83 | ||||||||
84 | ||||||||
85 | ||||||||
86 | ||||||||
87 | ||||||||
88 | ||||||||
89 | ||||||||
90 | ||||||||
91 | ||||||||
92 | ||||||||
93 | ||||||||
94 | ||||||||
95 | ||||||||
96 | ||||||||
97 | ||||||||
98 | ||||||||
99 | ||||||||
100 |